New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Amgen Inc.

AMGN

Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.

Revenue
+8.45%
EPS
+19.4%
Free cash flow
−14.0%
Total debt
−1.06%

Quarter to September 2026, against a year earlier

439.53 0.73 +0.17%
Market cap
$237.4B
P/E
25.2×
Fwd P/E FY26e
24.0×
Dividend yield
2.84%
F-score
7/9
ROIC
14.3%
Net debt / EBITDA
2.9×
Payout ratio
0.7×

Amgen Inc. (AMGN) Earnings & Analysis

Updated · Covers results through Q3 FY2026 · Earnings call · Latest filing 10-Q filed Nov 4, 2026 · How this is made

Latest quarter

Amgen reported Q3 FY2026 revenue of $10.4 billion, above the consensus of $10.0 billion. Adjusted earnings per share were $6.45, compared with the consensus estimate of $5.74.

Revenue increased from $9.6 billion a year earlier. Amgen’s filing said product sales growth was driven by volume, with Repatha among the medicines contributing to higher purchases. Repatha sales reached $1.1 billion, while the company’s rare-disease portfolio generated $1.6 billion in sales.

The filing said biosimilar launches contributed to declines in Prolia and XGEVA sales. Amgen reported Prolia sales of $632.0 million and XGEVA sales of $288.0 million.

Gross margin rose to 73.1% from 67.8%, and operating margin increased to 35.8% from 26.4%. The filing attributed lower operating expenses in part to reduced amortization of acquisition-related assets and the prior-year impact of Otezla impairment charges. Free cash flow was $3.7 billion, down from $4.2 billion a year earlier.

Q3 FY2026 Q3 FY2025 Change
Revenue $10.4 billion $9.6 billion 8.45%
Diluted EPS $7.08 $5.93 19.3%
Gross margin 73.1% 67.8% 5.4 percentage points
Operating margin 35.8% 26.4% 9.4 percentage points
Free cash flow $3.7 billion $4.2 billion −14.0%
Against the consensus Reported Consensus Result
Adjusted EPS $6.45 $5.74 Beat by 12.4%
Revenue $10.4 billion $10.0 billion Beat by 4.14%

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

Chief executive Robert Bradway said Amgen’s six key growth drivers grew 27% year over year and represented over 70% of third-quarter product sales. He identified Repatha, EVENITY and TEZSPIRE as medicines addressing disease areas where many patients remain untreated.

Bradway said Amgen increased research and development investment by 11% year over year and invested $600.0 million in capital expenditures during the quarter. He also said MariTide was advancing through Phase III development. CFO Thomas Dittrich said Amgen continued to expect a full-year non-GAAP operating margin of roughly 45.0% to 46.0% of product sales and expected operating expenses to rise sequentially in the fourth quarter.

Asked about IMDELLTRA, executive Murdo Gordon said an FDA-approved reduction in monitoring time for its existing second-line use was helping community oncology clinics initiate treatment. He said monitoring in the DeLLphi-305 study was shorter still and expressed hope that the label could improve further if the medicine is extended to frontline maintenance. Gordon said Amgen was working on regulatory filings and approvals.

When pressed on the commercial opportunity, Gordon said Amgen does not issue product-specific guidance. He said the addressable population changes by treatment setting and that patients in the earlier setting could remain on treatment longer.

Analysts also asked about dazodalibep in Sjögren’s disease. Executive James Bradner said results from the systemic study were difficult to read across to the symptomatic study because the patient populations differ. He said Amgen expected to have more to say after seeing the symptomatic-study data in the fourth quarter.

On MariTide access, Gordon said he expected reimbursement outside the U.S. to be tougher and hoped outcomes and diabetes data would help Amgen secure coverage in markets abroad.

Guidance

Amgen raised its FY2026 revenue guidance to $38.9 billion–$39.7 billion and its non-GAAP earnings-per-share outlook to $22.90–$23.70. The company also raised its GAAP earnings-per-share guidance to $18.34–$19.28.

Metric For Guide Previous guide Change
Operating margin, Non Gaap, product Sales FY2027 Amgen does not expect its FY2027 operating margin to decline from its FY2026 guidance. — —
Share repurchases FY2026 $3.0 billion $3.0 billion Held
Tax rate, non-GAAP FY2026 15.0%–16.5% 15.0%–16.5% Held
Revenue, Other Revenue FY2026 $1.9 billion — New
Operating expenses, Sga Q4 FY2026 Amgen expects higher SG&A expense sequentially in Q4 FY2026. — —
Operating expenses Q4 FY2026 Amgen expects a meaningful sequential increase in operating expenses in Q4 FY2026. — —
Operating margin, Non Gaap, product Sales FY2026 45.0%–46.0% — New
EPS, non-GAAP FY2026 $22.90–$23.70 $22.30–$23.50 Raised
Revenue FY2026 $38.9 billion–$39.7 billion $38.2 billion–$39.4 billion Raised
Capex FY2026 $2.6 billion $2.6 billion Held
Customers, Repatha FY2026 3,000,000 — —
Tax rate, GAAP FY2026 14.5%–16.0% 14.5%–16.0% Held
EPS, GAAP FY2026 $18.34–$19.28 $15.80–$17.08 Raised
Revenue, Other FY2026 $1.9 billion — New
Operating margin, Non Gaap Product Sales FY2026 45.0%–46.0% — New